Dr. Niclas Stiernholm reports
TRILLIUM THERAPEUTICS ANNOUNCES PUBLICATION HIGHLIGHTING ACTIVITY OF TTI-621 IN SEZARY SYNDROME PATIENTS
Trillium Therapeutics Inc. has published data highlighting the role of TTI-621 in treating patients with Sezary syndrome (SS), a form of cutaneous T-cell lymphoma (CTCL).
The paper titled "Targeting CD47 in Sezary syndrome with SIRPaFc," published in the April 9 issue of Blood Advances, demonstrates that TTI-621 (SIRPa-IgG1 Fc) triggers macrophage-mediated phagocytosis of Sezary cells and reduces tumour load in SS patients following intravenous administration. Four of five heavily pretreated SS patients had a decrease in the dominant malignant clone and other markers of tumour burden after a single infusion of TTI-621. "We continue to be excited by the monotherapy data emerging from our TTI-621 clinical studies," stated Dr. Niclas Stiernholm, president and chief executive officer of Trillium Therapeutics. "The results in this manuscript provide further support for investigating the therapeutic potential of our novel CD47-blocking agent in CTCL patients."
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.